EcoDrugPlus

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSMZEG00005013319
Gene Symbol: EZH2
3 Cross references
228 Possible Orthologues:

Ephrin Type-B Receptor 4

Ensembl ID : ENSMZEG00005027688
Gene Symbol: LOC101467581
3 Cross references
168 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSMZEG00005024555
Gene Symbol: LOC101483528
3 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2

Ensembl ID : ENSMZEG00005014310
Gene Symbol: EPHX2
3 Cross references
203 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSMZEG00005014420
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSMZEG00005008884
Gene Symbol: ERBB3
3 Cross references
208 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSMZEG00005010084
Gene Symbol: ERBB4
3 Cross references
47 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSMZEG00005014678
Gene Symbol: ERBB4
3 Cross references
230 Possible Orthologues:

Estrogen Receptor

Ensembl ID : ENSMZEG00005017853
Gene Symbol: LOC101479381
3 Cross references
215 Possible Orthologues:

Estrogen Receptor 2

Ensembl ID : ENSMZEG00005001558
Gene Symbol: ESR2
2 Cross references
208 Possible Orthologues:

Estrogen Receptor Beta

Ensembl ID : ENSMZEG00005004568
Gene Symbol: LOC101469072
3 Cross references
198 Possible Orthologues:

Estrogen-Related Receptor Gamma

Ensembl ID : ENSMZEG00005010067
Gene Symbol: LOC101481777
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).